N. Scott Fine is CEO at Cyclo Therapeutics, Inc. (CTDH). They have made 12 open-market trades across 3 companies since 2010, most recently 2023-10-20.
CIK 0001163556
11 open-market purchases totalling $896K since 2014, against 1 sale. Across 7 scored buys the stock is down 20.8% at ninety days, and 17.9 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 29% | 43% | 14% |
| Avg Move | +2.8% | +1.1% | -20.8% |
| Alpha | +3.7% | +2.5% | -17.9% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CYTH | BUY | 2023-04-20 | 2023-04-24 | $0.71 | $425K | +60.7% | +63.1% | +65.6% |
| CYTH | BUY | 2022-02-07 | 2022-02-07 | $3.58 | $37K | -7.1% | -8.2% | -40.8% |
| CYTH | BUY | 2022-01-19 | 2022-01-19 | $3.89 | $19K | -8.0% | -16.0% | -29.8% |
| CYTH | BUY | 2021-12-15 | 2021-12-15 | $3.89 | $19K | -13.5% | +5.7% | -34.7% |
| CYTH | BUY | 2021-12-02 | 2021-12-02 | $4.93 | $25K | -20.0% | -19.0% | -33.1% |
| CYTH | BUY | 2021-11-19 | 2021-11-19 | $5.25 | $26K | -5.1% | -21.1% | -35.6% |
| CYTH | BUY | 2021-09-15 | 2021-09-15 | $6.35 | $32K | +12.6% | +2.9% | -37.2% |
| CTDH | BUY | 2020-04-24 | 2020-04-27 | $0.10 | $73K | N/A | N/A | N/A |
| CTDH | BUY | 2019-09-18 | 2019-09-19 | $0.18 | $2K | N/A | N/A | N/A |
| CTDH | BUY | 2019-07-31 | 2019-07-31 | $0.25 | $13K | N/A | N/A | N/A |
| CTDH | BUY | 2014-02-19 | 2014-02-21 | $0.05 | $225K | N/A | N/A | N/A |
| CEDC | SELL | 2010-05-11 | 2010-05-13 | $29.50 | $221K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.